U.S., Oct. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07220915) titled 'Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections' on Sept. 30.
Brief Summary: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Panzyga for Prevention of Major Infection in Patients with Hypogammaglobulinemia and Autoimmune or Rheumatic Conditions Receiving Treatment with B-cell Depletion Therapy
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Hypogammaglobulinemia
Autoimmune Conditions
Rheumatic Conditions
Infections
Intervention:
DRUG: Panzyga, 10% Intravenous Solution
Panzyga is a 10% Ig formulatio...